申请人:Felding Jakob
公开号:US20070299102A1
公开(公告)日:2007-12-27
The present invention relates to substituted 3,3-diphenyl-1,3-dihydro-indol-2-one compounds, and the use of such compounds for the preparation of a medicament for the treatment of cancer in a mammal. It is postulated that treatment of cancers is achieved in which inhibition of protein synthesis and/or inhibition of activation of the mTOR pathway is an effective method for reducing cell growth. Examples of such cancers are breast cancer, renal cancer, multiple myeloma, leukemia, glia blastoma, rhabdomyosarcoma, prostate, soft tissue sarcoma, colorectal sarcoma, gastric carcinoma, head and neck squamous cell carcinoma, uterine, cervical, melanoma, lymphoma, and pancreatic cancer. A particular subclass of compounds are represented by the formula (II)
wherein at least one of X
1
and X
2
is a heteroatom substituent, e.g. 6-chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one.
本发明涉及取代的3,3-二苯基-1,3-二氢吲哚-2-酮化合物,以及使用这些化合物制备哺乳动物治疗癌症的药物。据推测,通过抑制蛋白质合成和/或抑制mTOR通路的激活来减少细胞生长是治疗癌症的有效方法。这些癌症的例子包括乳腺癌、肾癌、多发性骨髓瘤、白血病、胶质母细胞瘤、横纹肌肉瘤、前列腺癌、软组织肉瘤、结肠肉瘤、胃癌、头颈部鳞状细胞癌、子宫颈癌、黑色素瘤、淋巴瘤和胰腺癌。化合物的一个特定亚类由公式(II)表示,其中X1和X2中至少一个是杂原子取代基,例如6-氯-3,3-双(4-羟基苯基)-7-甲基-1,3-二氢吲哚-2-酮。